Stay updated with breaking news from Takeaim Leukemia Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance...
LEXINGTON - Curis, Inc., , a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor for the treatment of hematologic...
/PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple...
Curis, Inc. announced that the U.S. Food and Drug Administration has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. Further, the recommended phase 2 dose ...
Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its business update and financial results for the third quarter... | November 10, 2022